LONDON, Dec. 19, 2016 /PRNewswire/ -- The trend favoring biological drugs as a percent of all drugs continues to accelerate. Most are injectables and many require volumes that exceed 1 mL per dose, the de facto limit for comfortable and safe patient self-administration. As result, the majority of biologicals are supplied for delivery via infusion. The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the efforts to develop and commercialize high volume drug delivery products that can be administered subcutaneously. We expect the number of therapeutic drugs in this class to grow significantly by the end of the decade, creating significant opportunities for high volume subcutaneous drug delivery products.
What You Will Learn
- Provides detailed analysis of therapeutic injectables with high volume dosing requirements that have been developed for subcutaneous administration over extended time periods.
- Analyzes therapeutic demand drivers and evaluates product activity in eleven product segments
- Profiles devices for delivering high volume drugs subcutaneously and assesses design factors and material selection issues
- Examines high volume subcutaneous drug products in development, and analyzes their potential commercial impact
- Provides market data and forecasts to 2020
- Profiles injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations
- Evaluates the impact of economic, technology, and regulatory factors
Download the full report: https://www.reportbuyer.com/product/3858946/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/high-volume-subcutaneous-drug-delivery-300381128.html